"Founded in 2008 Chicago Clinical Research Institute, Inc. (CCRII) is a multi-specialty dedicated research facility conducting phase II to phase IV clinical trials. CCRII has a combined 50 years of clinical research experience and has conducted more than 250 clinical research trials in the therapeutic areas of Diabetes Mellitus Type II, Hypertension, Hyperlipidemia, Chronic Kidney Disease, Cardiovascular Disease, Osteoarthritis, Rheumatoid Arthritis, Pain Management, Neuropathy, Gynecology, Male Health, Ophthalmology, and Oncology"

During the past decade, Chicago Clinical Research Institute, Inc. conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 9 clinical trials were completed, i.e. on average, 69.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 8 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chicago Clinical Research Institute, Inc." #1 sponsor was "Pfizer" with 6 trials, followed by "Regeneron Pharmaceuticals" with 2 trials sponsored, "Unity Biotechnology, Inc." with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored and "Novartis Pharmaceuticals" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chicago Clinical Research Institute, Inc." #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Premier Research Group plc" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Chicago Clinical Research Institute, Inc." are "Osteoarthritis, Knee" (4 trials), "Osteoarthritis, Hip" (3 trials), "Knee Osteoarthritis" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Chicago Clinical Research Institute, Inc." in a lesser frequency.

Most popular intervention types in "Chicago Clinical Research Institute, Inc." are "Drug" (15 trials), "Biological" (4 trials), "Other" (4 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Tanezumab 2.5 mg" (2 trials), "AC-201, 25mg" (1 trials), "AC-201, 50mg" (1 trials) and "AC-201, 75mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chicago Clinical Research Institute, Inc." are 17 trials for "All" genders.

Currently, there are NaN active trials in "Chicago Clinical Research Institute, Inc.". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Chicago Clinical Research Institute, Inc., undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Chicago Clinical Research Institute, Inc., 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".